@article {1549006,
	title = {Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary human retinal microvascular endothelial cells},
	journal = {Biomed Pharmacother},
	volume = {133},
	year = {2021},
	month = {2021 Jan},
	pages = {110999},
	abstract = {Abnormal angiogenesis is associated with intraocular diseases such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, and current therapies for these eye diseases are not satisfactory. The purpose of this study was to determine whether capilliposide B (CPS-B), a novel oleanane triterpenoid saponin derived from Lysimachia capillipes Hemsl, can inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis signaling events and cellular responses in primary human retinal microvascular endothelial cells (HRECs). Our study revealed that the capilliposide B IC for HRECs was 8.5 μM at 72 h and that 1 μM capilliposide B specifically inhibited VEGF-induced activation of VEGFR2 and its downstream signaling enzymes Akt and Erk. In addition, we discovered that this chemical effectively blocked VEGF-stimulated proliferation, migration and tube formation of the HRECs, suggesting that capilliposide B is a promising prophylactic for angiogenesis-associated diseases such as proliferative diabetic retinopathy.},
	issn = {1950-6007},
	doi = {10.1016/j.biopha.2020.110999},
	author = {Han, Haote and Yang, Yanhui and Wu, Zhipan and Liu, Bing and Dong, Lijun and Deng, Hongwei and Tian, Jingkui and Lei, Hetian}
}
